ストックスクリーナーアプリを入手
83.89
1.38%
-1.17
前日終値:
$85.06
開ける：
$85.89
24時間の取引高:
1.21M
Relative Volume:
0.38
時価総額：
$31.66B
収益：
$4.82B
当期純損益:
$930.40M
株価収益率:
35.88
EPS:
2.3381
ネットキャッシュフロー:
$1.43B
1週間 パフォーマンス:
-0.49%
1か月 パフォーマンス:
-0.93%
6か月 パフォーマンス:
+33.26%
1年 パフォーマンス:
+26.70%
1日の値動き範囲:
$83.56
$86.18
1週間の範囲:
$82.94
$86.60
52週間の値動き範囲:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
83.89 | 31.66B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
102.53 | 177.42B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.96 | 118.91B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
280.06 | 107.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.45 | 61.51B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.91 | 49.52B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-07 | 開始されました | Barclays | Overweight |
| 2026-06-23 | 開始されました | Deutsche Bank | Buy |
| 2026-05-12 | 開始されました | The Benchmark Company | Buy |
| 2026-03-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
DexCom, Inc. (DXCM) options chain – Yahoo Finance - Yahoo Finance Singapore
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Evercore ISI Adjusts Price Target on DexCom to $110 From $90 - marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - www.marketscreener.com
DexCom Inc (DXCM) Stock Down 4.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
DexCom Falls as Investors Appear to Take Profits Ahead of Earnings - Quiver Quantitative
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading - Business Wire
Dexcom Launches Largest Dexcom U Program Season Yet, Supporting College Athletes with Diabetes (DXCM) - GuruFocus
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
DexCom stock gains 1.22 percent ahead of October earnings - AD HOC NEWS
Continuous Glucose Monitoring Market Size, Share [2026-2034] - Fortune Business Insights
Dexcom Hit With New Lawsuits Over G7 Monitor Failures - Medical Device and Diagnostic industry
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - TradingView
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup - ChartMill
DXCM Maintains by RBC Capital -- Price Target Raised to $105 - GuruFocus
ShinyHunters new leak site lists O’Reilly and Dexcom breaches - cybernews.com
DEXCOM INC : RBC RAISES TARGET PRICE TO $105 FROM $90 - Moomoo
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia - GlobeNewswire Inc.
RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating - marketscreener.com
Under a preset trading plan, DexCom (DXCM) EVP Sadie Stern sells 2,565 shares. - Stock Titan
Here's Why DexCom (DXCM) is a Strong Growth Stock - Zacks Investment Research
Why DexCom Could Be the Big Winner Out of Oura’s IPO - Barron's
Dexcom Data Points to a CGM Awareness Gap, and Room to Grow - Medical Product Outsourcing
The Insider Report: The Leaders Have Taken Off - Benzinga
Dexcom Publishes New Report During Easd 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - marketscreener.com
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - Dexcom Investor Relations
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - The Joplin Globe
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - Business Wire
Dexcom stock slips 2.01 percent ahead of the open - AD HOC NEWS
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow - Yahoo Finance
DexCom stock trades below its 52-week high as Truist lifts target - AD HOC NEWS
Dexcom stock falls 1.1 percent ahead of the open - AD HOC NEWS
DexCom, Inc. (DXCM) latest stock news and headlines - uk.finance.yahoo.com
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer - Yahoo Finance
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom, Inc. (DXCM) Stock Price, News, Quote & History - Yahoo! Finance Canada
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval - ACCESS Newswire
American Diversified Holdings Corporation (ADHC) Seeks Funding; Advances Dexcom App Integration - TradingView
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval - TradingView
Dexcom stock heads into the open after Nasdaq gains 0.45 percent - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings and Promising Growth in the Medical Device Sector - DirectorsTalk Interviews
Dexcom Inc. stock gains on leadership change and strong recent performance - AD HOC NEWS
Dexcom Inc. stock gains on fresh Truist and TD Cowen price targets - AD HOC NEWS
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Truist Securities Adjusts DexCom Price Target to $102 From $93, Maintains Buy Rating - Yahoo Finance
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom, Inc. Announces Appointment of Jereme Sylvain as Executive Vice President and Chief Operating Officer, Effective September 14, 2026 - marketscreener.com
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
Dexcom Inc (DXCM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SADIE STERN | Officer |
Sep 28 '26 |
Proposed Sale |
86.15 |
2,565 |
220,975 |
0 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Sale |
84.04 |
6,539 |
549,538 |
29,293 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Proposed Sale |
84.04 |
6,539 |
549,538 |
0 |
| MICHAEL BROWN | Officer |
Sep 15 '26 |
Proposed Sale |
84.04 |
1,700 |
142,868 |
0 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Sale |
84.02 |
1,550 |
130,231 |
35,832 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Proposed Sale |
84.02 |
1,550 |
130,231 |
0 |
| JEREME SYLVAIN | Officer |
Sep 10 '26 |
Proposed Sale |
83.27 |
3,638 |
302,936 |
0 |
| Sylvain Jereme M | EVP, Chief Financal Officer |
Sep 10 '26 |
Sale |
83.27 |
3,638 |
302,936 |
146,828 |
| SADIE STERN | Officer |
Aug 27 '26 |
Proposed Sale |
88.37 |
2,565 |
226,669 |
0 |
1.50%
0.72%
大文字化:
|
ボリューム (24 時間):